Nanobac Pharmaceuticals Films Stunning Details of

Seite 1 von 2
neuester Beitrag: 29.10.06 18:14
eröffnet am: 22.08.06 23:29 von: horstpaul Anzahl Beiträge: 38
neuester Beitrag: 29.10.06 18:14 von: Bobby333 Leser gesamt: 4621
davon Heute: 1
bewertet mit 2 Sternen

Seite:
| 2  

22.08.06 23:29
2

1028 Postings, 7471 Tage horstpaulNanobac Pharmaceuticals Films Stunning Details of



Nanobac Pharmaceuticals Films Stunning Details of Nanoparticles Using New Technology
TUESDAY, AUGUST 22, 2006 12:26 PM

TAMPA, Fla., Aug 22, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced that its scientists have obtained new details about interactions of drugs with calcifying nanoparticles (CNPs), known also as nanobacteria, using award-winning light microscope technology.

The images show nanoparticles being affected by a therapeutic drug ingredient, and offer proof of concept that new microscope technology can detect real-time processes surrounding calcifying nanoparticles, which contain harmful calcifying constituents found in diseases such as kidney stones and atherosclerosis.

"This marks a watershed in the Company's ability to witness interactions between drug ingredients and calcifying nanoparticles," commented Nanobac Co-Chairman Dr. Benedict Maniscalco. "These images also demonstrate clear differences between CNPs and inorganic apatite, offering further proof that CNPs are distinct from inorganic apatite particles."

The video and still images were obtained by Nanobac scientists Dr. Neva Ciftcioglu and Grace Mathew at Nanobac laboratories in the NASA Johnson Space Center in Houston. The images will be released once the processes they recorded have been validated.

The success is an early result of a collaboration agreement between Nanobac and the Fetzer Memorial Trust to photograph the replication cycle of disease-related calcifying particles (also known as nanobacteria or Calcifying Nanoparticles), using light microscopes to break the 200 nanometer ("nm") resolution barrier. The breakthrough may allow Nanobac scientists to determine if calcification, which occurs in most diseases on the leading causes of death list, has a biological mechanism, which would make it susceptible to therapy.

Until now, scientists had to 'fix' or inactivate such nanoparticles to see below the 200 nmhreshold using electron microscopy, which precluded observing real-time processes.

The "CytoViva"(TM) microscope system, developed at Auburn University and marketed by Aetos Technologies, can resolve details at or below 100 nm and detect particles as small as 50 nm, representing a significant improvement over conventional light microscopes. The CytoViva(TM) system was selected in June by R&D Magazine as one of the top 100 most technologically significant products introduced to the marketplace in 2006. The award is often referred to as the 'Oscar of Inventions.'

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .  

12.09.06 20:05

1028 Postings, 7471 Tage horstpaulNanobac KZ 0,91$ aktuell 0,123$

Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.91
TUESDAY, SEPTEMBER 12, 2006 8:01 AM

TAMPA, Fla., Sep 12, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.

The free report is available at: http://www.wallstreetresources.net/pdf/fc/NNBP.pdf. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm with over 10 years of experience providing analysis for emerging growth companies and information to the investment community.

"We are very excited that Wall Street Resources has seen fit to issue an overall evaluation of our company, and with a short-term target value of $0.91 per share. Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles (CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals. "The quality of Mr. Silver's research, coupled with the comprehensive analysis of our business plan, will assist the Company in gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmceuticals, Inc."

Mr. Silver stated, "Nanobac's extensive body of scientific research in the study of Calcifying Nanoparticles represents a paradigm shift in the understanding of calcific disease. We believe that Nanobac's developments of diagnostic and therapeutic products will revolutionize the medical industry. With the market for calcific diseases currently exceeding $500 billion per year, we believe that the commercial opportunities for Nanobac's products are virtually limitless."

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .

About Wall Street Resources, Inc.:

Wall Street Resources, Inc. and its affiliated site http://www.wallstreetresources.net is a leading source for information on micro-to-small capital publicly traded companies. Wall Street Resources (WSR) acts as a conduit between micro-to-small capital company investors and emerging growth companies through its proprietary financial publications including daily and monthly newsletters, as well as comprehensive 20-50 page featured company reports. To sign up to receive WSR's financial publications go to: http://www.wallstreetresources.net/signup_promotion.asp. WSR also provides business consulting services to help corporate executives by writing analytical reports, building financial models, and developing business plans.

Disclaimer -- We, our affiliates, and any officer, director or stockholder or any member of their families may have a position in and may from time to time purchase or sell any securities discussed in our financial publications. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. Our associates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in our reports. WSR is a consultant to the Company and has received $15,000 in cash and 466,666 shares of 144 restricted stock for due diligence fees and consulting services from July of 2006 through February of 2007.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

SOURCE: Nanobac Pharmaceuticals, Inc.

mfg
horstpaul  

15.09.06 18:30

1028 Postings, 7471 Tage horstpaul100% in 4 Tage bei hohen Umsätzen

und sie läuft und läuft und läuft und keiner bekommt es mit :p

mfg

horstpaul  

18.09.06 19:09

1028 Postings, 7471 Tage horstpaul150% in 5 Tagen :)

und falls die wirklich auf die 0,91 US$ laufen, sind noch fast 300% drin :D. Umsätze sehen gut aus.

mfg

horstpaul  

18.09.06 19:21

1028 Postings, 7471 Tage horstpaul3-Jahres Chart zeigt noch viel Luft nach oben.



sonst keiner investiert?

mfg

horstpaul  

19.09.06 18:44

1028 Postings, 7471 Tage horstpaulUnd die Rally geht weiter :D

0.274 Change:
+0.034
Percent Change:
+14.17%



 

21.09.06 16:29

4308 Postings, 6931 Tage Nukem91 Cent Kursziel, kurzfristig.

Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.91
Tuesday September 12, 8:01 am ET

TAMPA, Fla.--(BUSINESS WIRE)--Sept. 12, 2006--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") today announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.

ADVERTISEMENT
The free report is available at: http://www.wallstreetresources.net/pdf/fc/NNBP.pdf. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm with over 10 years of experience providing analysis for emerging growth companies and information to the investment community.

"We are very excited that Wall Street Resources has seen fit to issue an overall evaluation of our company, and with a short-term target value of $0.91 per share. Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles (CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals. "The quality of Mr. Silver's research, coupled with the comprehensive analysis of our business plan, will assist the Company in gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmceuticals, Inc."

Mr. Silver stated, "Nanobac's extensive body of scientific research in the study of Calcifying Nanoparticles represents a paradigm shift in the understanding of calcific disease. We believe that Nanobac's developments of diagnostic and therapeutic products will revolutionize the medical industry. With the market for calcific diseases currently exceeding $500 billion per year, we believe that the commercial opportunities for Nanobac's products are virtually limitless."

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .  

21.09.06 16:30

4308 Postings, 6931 Tage Nukem91 Cent

Zu teuer gibts nicht, hat der Analyst seine Arbeit gut gemacht, sollten wir morgen weiter nach oben ziehen.  

21.09.06 18:57

560 Postings, 5123 Tage Bobby333Habe ich am Dienstag verkauft...

und die wird die nächsten Tage voll absacken, weil die Analysten und Ihre Freunde schon draußen sind und zu dem noch eine schöne Provision kassiert haben.  

Gruß  

21.09.06 19:42

1028 Postings, 7471 Tage horstpaulSoviele Zocker

werden bei dem Wert nicht dabei sein, zumindest ist in den Deutschen Boards so gut wie nix über Nanobac zu finden. Die Analysten haben nur 466,666 Shares bekommen und denke nicht das die das hohe Volumen zu verantworten haben.

Zumindest war die Aktie massiv überkauft, was sich gestern und heute neutralisiert hat und außerdem wurde das GAP geschlossen.

Würde sagen, dass es zukünftig auf den Newsflow ankommt, wohin sich Nanobac bewegt. Finde die Aktie auf alle Fälle interessant und der H&A Nanofond wird die sicherlich nicht aus Spass im Portfolio haben ;).

mfg

horstpaul  

21.09.06 22:27

560 Postings, 5123 Tage Bobby333@horstpaul

bin ganz deiner Meinung. Es kommt in der nächsten Zeit ganz auf den Newsflow an. Wenn die News aber ausbleiben, fürchte ich wird das Ding bis zu 30% seines Wertes einbüßen. Ist meine persönliche Erfahrung, die ich in der letzten Zeit sammeln konnte, wo es ähnliche Fälle gab.

Gruß  

25.09.06 10:05

4308 Postings, 6931 Tage Nukem30+ X, Kursziel für heute

Der Ausverkauf ist gestoppt. Starkes Kaufsignal. Nanobac steht, wenn deren patentiertes Verfahren wirkt, in einem 500 Mrd. Markt und dass ganz alleine. Auch so schon wächst das Unternehmen heftig.  

25.09.06 10:17

4308 Postings, 6931 Tage NukemStocks to watch!

Nanobac unbedingt heute auf den Radar stellen!  

25.09.06 10:39

4308 Postings, 6931 Tage NukemTicker!

kam gerade über die Ticker:

NANOBAC PHARMACEUTICALS aufmerksamaufmerksamaufmerksamaufmerksam



OTCPicks.com: Daily Market Movers Digest Stock Alerts, Monday, September 25th, EDNE, XKEM, GLIF, NNBP, ABTG
9/25/2006

Sep 25, 2006 (M2 PRESSWIRE via COMTEX News Network) --
Today our stock watch alerts today include stock alerts for Eden Energy Corporation (OTCBB: EDNE), Xechem International, Inc. (OTCBB: XKEM), Grant Life Sciences, Inc. (OTCBB: GLIF), Nanobac Pharmaceuticals, Inc. (OTCBB: NNBP), and Ambient Corporation (OTCBB: ABTG)

Visit http://www.otcpicks.com to register for our FREE Daily Market Mover\'s Digest Newsletter and Stock Alerts  

25.09.06 10:51

4308 Postings, 6931 Tage NukemWarten bis zum Handelsbeginn

In dem Board sind auch alle bullish. Jetzt noch so lange warten bis 15.30 Uhr......

http://www.thelion.com/bin/forum.cgi?sf=NNBP.OB  

25.09.06 17:28

560 Postings, 5123 Tage Bobby333News von heute




http://biz.yahoo.com/bw/060925/20060925005404.html?.v=1  

04.10.06 17:52

1028 Postings, 7471 Tage horstpaulDa sind schon die ersten wirklich guten news :)

Nanobac Pharmaceuticals Inc. Signs Agreement with American Health Associates Clinical Laboratories to Provide Calcifying Nanoparticle Tests in the United States

TAMPA, Fla., Oct 04, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (NNBP)  ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk. AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S.

"Nanobac has partnered with AHA for this important test so that our company can focus on its core R&D while continuing to make available and expanding the availability of these tests for research purposes," explained Nanobac Co-Chairman Dr. Benedict Maniscalco. "For the first time ever we now have a qualified laboratory in the U.S. where physicians can send blood samples for testing, along with authorized stations where patients can go to have blood drawn and know that the samples will be properly handled," Dr. Maniscalco added.

The tests can detect CNP antigens and antibodies. Analysis is done by Nanobac's own laboratories in Kuopio Finland; the only lab in the world capable of such analysis. Nanobac has performed thousands of such tests worldwide since the year 2000.

(a) (Note to editors: the term "Calcifying Nanoparticle (CNP)" has been adopted in recently published literature to help distinguish these particles from bacteria.)

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria." The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Quelle: http://bigcharts.marketwatch.com/news/...570048&symb=NNBP&sid=1501681

mfg
horstpaul  

04.10.06 18:04

560 Postings, 5123 Tage Bobby333@ Vielleicht werden jetzt einige aufmerksam ! o. T.

19.10.06 06:07

15875 Postings, 6910 Tage Calibra21Achtung Kaufsignal! o. T.

 
Angehängte Grafik:
nnbp.gif
nnbp.gif

20.10.06 06:31

15875 Postings, 6910 Tage Calibra21Kaufsignal hat sich bestätigt

Keiner an Bord?  

20.10.06 09:44

15875 Postings, 6910 Tage Calibra21+37 % in Frankfurt o. T.

20.10.06 09:47

15875 Postings, 6910 Tage Calibra21Welches Kursziel ?

200 % oder 300 % *lol*

...Die Analysten von Wall Street Research hätten für die Aktie ein Kursziel von 0,91 USD in Aussicht gestellt. Die "Hot Stocks Investor"-Experten würden das auf kurze Sicht aber als etwas zu hoch ansehen. Ein Run bis in den Bereich von 50 bis 60 Cents könnte aber durchaus noch drin sein...
 

20.10.06 09:57

15875 Postings, 6910 Tage Calibra21Hammeranalyse!

Unbedingt ansehen!

http://www.wallstreetresources.net/pdf/fc/NNBP.pdf  

20.10.06 10:01

742 Postings, 5014 Tage popelfuchsNa da lohnt sich ja noch ein Einstieg

Die Analyse ist ja der Knaller ! Da wird ja dann im Jahr 2007 das Nasdaq-Listing vor der Tür stehen ! Also Kursziel 1 $ ist realistisch anzusehen !  

20.10.06 10:07

15875 Postings, 6910 Tage Calibra21Genau wie GLIF wird anscheinend

ein Test entwickelt. Zwar bzgl. anderer Krankheiten aber wie gross das Potenzial bei solchen Testentwicklern ist sah man an GLIF!

http://biz.yahoo.com/bw/061004/20061004005580.html?.v=1

...have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases...  

Seite:
| 2  
   Antwort einfügen - nach oben